FAST NEWS: JW Therapeutics’ revenue soars on growing lymphoma drug sales
The latest: Biotech company JW (Cayman) Therapeutics Co. Ltd. (2126.HK) said on Wednesday its revenue surged 373% to 146 million yuan ($21.2 million) last year, while its non-GAAP net loss narrowed…
2126.HK
Recent Articles
RELATED ARTICLES
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK
-
Akeso marks profit milestone with swift rights issue
9926.HK
-
Test results for new cancer drug take Akeso investors on wild ride
9926.HK
-
Ascentage Pharma soars on deal with cancer drug competitor
6855.HK
-
Hutchmed scores U.S. success with cancer drug, but profits still dip
HCM.US 0013.HK
Discover hidden China stock gems in our weekly newsletter